UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 112

Sortiert nach

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?

British journal of cancer, 2020-02, Vol.122 (4), p.453-454

Niegisch, Günter

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST)

European urology, 2023-07, Vol.84 (1), p.25-31

2023

Link zum Volltext

Verfügbarkeit prüfen

Does robotic radical cystectomy affect oncological outcomes in bladder cancer patients?

Aktuelle Urologie, 2022-04, Vol.53 (2), p.153

2022

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma

PloS one, 2017-04, Vol.12 (4), p.e0176287-e0176287

2017

Link zum Volltext

Verfügbarkeit prüfen

Enhancement of human bladder carcinoma cell chemosensitivity to Mitomycin C through quasi-monochromatic blue light (λ = 453 ± 10 nm)

Journal of photochemistry and photobiology. B, Biology, 2022-11, Vol.236, p.112582, Article 112582

2022

Link zum Volltext

Verfügbarkeit prüfen

Exposure of Bladder Cancer Cells to Blue Light (λ = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine

International journal of molecular sciences, 2024-05, Vol.25 (9), p.4868

2024

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

BMC cancer, 2020-03, Vol.20 (1), p.230-230, Article 230

2020

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens

European urology, 2018-03, Vol.73 (3), p.462-468

2018

Link zum Volltext

Verfügbarkeit prüfen

Die Interdisziplinäre Arbeitsgruppe BlasenCarcinom (IABC): Optimierung der Versorgung von Blasenkrebspatienten

Forum (Heidelberg), 2021-09, Vol.36 (4), p.314-315

Niegisch, Günter

2021

Link zum Volltext

Verfügbarkeit prüfen

Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma

Methods in molecular biology (Clifton, N.J.), 2023, Vol.2684, p.293

Niegisch, Günter

2023

Link zum Volltext

Verfügbarkeit prüfen

New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma

Journal of cellular and molecular medicine, 2024-05, Vol.28 (9), p.e18342-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Many Different LINE-1 Retroelements Are Activated in Bladder Cancer

International journal of molecular sciences, 2020-12, Vol.21 (24), p.9433

2020

Link zum Volltext

Verfügbarkeit prüfen

Cognitive function in patients undergoing cystectomy for bladder cancer – results from a prospective observational study

Therapeutic advances in urology, 2022-03, Vol.14, p.17562872221087660-17562872221087660

2022

Link zum Volltext

Verfügbarkeit prüfen

Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells

Genes, 2021-02, Vol.12 (2), p.260

2021

Link zum Volltext

Verfügbarkeit prüfen

Enfortumab Vedotin and Pembrolizumab — A New Perspective on Urothelial Cancer

The New England journal of medicine, 2024-03, Vol.390 (10), p.944-946

Niegisch, Günter

2024

Link zum Volltext

Verfügbarkeit prüfen

Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment

Molecules (Basel, Switzerland), 2021-02, Vol.26 (5), p.1294

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study

Scientific reports, 2023-10, Vol.13 (1), p.17378-17378, Article 17378

2023

Link zum Volltext

Verfügbarkeit prüfen

The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells

Molecular cancer, 2015-05, Vol.14 (1), p.108-108, Article 108

2015

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms

Molecular cancer therapeutics, 2016-02, Vol.15 (2), p.299-312

2016

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines

Targeted oncology, 2016-12, Vol.11 (6), p.783-798

2016

Link zum Volltext

Verfügbarkeit prüfen

Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells

Frontiers in immunology, 2021-11, Vol.12, p.782448-782448

2021

Link zum Volltext

Verfügbarkeit prüfen

Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC)

Urologic oncology, 2014-10, Vol.32 (7), p.966-974

2014

Link zum Volltext

Verfügbarkeit prüfen

Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1

Scientific reports, 2020-03, Vol.10 (1), p.3808, Article 3808

2020

Link zum Volltext

Verfügbarkeit prüfen

Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1

Cancers, 2020-02, Vol.12 (2), p.337

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 112

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(100)
Mit Volltextzugriff
(102)

Publikationsform

Artikel
(110)
Buchkapitel
(2)

Sprache

Englisch
(100)
Deutsch
(12)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(90)
Life Sciences & Biomedicine
(86)
Humans
(64)
Oncology
(48)
Bladder Cancer
(38)
Urothelial Carcinoma
(38)
Urology & Nephrology
(33)
Cell Line, Tumor
(26)
Cancer
(23)
Male
(23)
Aged
(22)
Middle Aged
(21)
Urology
(21)
Apoptosis
(20)
Female
(20)
Urinary Bladder Neoplasms - Drug Therapy
(19)
Urinary Bladder Neoplasms - Pathology
(19)
Urinary Bladder Neoplasms - Genetics
(17)
Urothelial Cancer
(17)
Chemotherapy
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?

Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST)

Does robotic radical cystectomy affect oncological outcomes in bladder cancer patients?

Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma

Enhancement of human bladder carcinoma cell chemosensitivity to Mitomycin C through quasi-monochromatic blue light (λ = 453 ± 10 nm)

Exposure of Bladder Cancer Cells to Blue Light (λ = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens

Die Interdisziplinäre Arbeitsgruppe BlasenCarcinom (IABC): Optimierung der Versorgung von Blasenkrebspatienten

Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma

New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma

Many Different LINE-1 Retroelements Are Activated in Bladder Cancer

Cognitive function in patients undergoing cystectomy for bladder cancer – results from a prospective observational study

Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells

Enfortumab Vedotin and Pembrolizumab — A New Perspective on Urothelial Cancer

Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment

Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study

The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells

Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines

Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells

Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC)

Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection – A 13-year follow-up analysis of a phase III trial cohort

Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1

Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1

Suchergebnisse filtern